ReviewMovement disorders clinical practice2015
Current Concepts in the Treatment of Multiple System Atrophy.
Review in Movement disorders clinical practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Rapidly Progressive Multiple System Atrophy-Cerebellar Type in a 52-Year-Old Woman: Diagnostic Challenges in a Resource-Limited Setting.Clinical case reports · 2025Article
- Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes.Antioxidants (Basel, Switzerland) · 2023Article
- Primary lateral sclerosis plus parkinsonism: a case report.BMC neurology · 2023Article
- Symptomatic Care in Multiple System Atrophy: State of the Art.Cerebellum (London, England) · 2023Review
- Multiple system atrophy-cerebellar: A case report and literature review.Radiology case reports · 2023Article
- Ataxias: Hereditary, Acquired, and Reversible Etiologies.Seminars in neurology · 2023Article
- Multiple system atrophy.Nature reviews. Disease primers · 2022Review
- Determinants of cognitive impairment in multiple system atrophy: Clinical and genetic study.PloS one · 2022Article
- A historical review of multiple system atrophy with a critical appraisal of cellular and animal models.Journal of neural transmission (Vienna, Austria : 1996) · 2021Review
- Effectiveness of Levodopa in Patients with Multiple System Atrophy and Associated Clinicopathological Features.Internal medicine (Tokyo, Japan) · 2021Article
- Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord.Frontiers in molecular neuroscience · 2021Review
- Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions.Translational neurodegeneration · 2020Review
- Structural Imaging and Parkinson's Disease: Moving Toward Quantitative Markers of Disease Progression.Journal of Parkinson's disease · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MSA is a progressive neurodegenerative disorder characterized by autonomic failure and a variable combination of poor levodopa-responsive parkinsonism and cerebellar ataxia (CA). Current therapeutic management is based on symptomatic treatment. Almost one third of MSA patients may benefit from l-dopa for the symptomatic treatment of parkinsonism, whereas physiotherapy remains the best therapeutic option for CA. Only midodrine and droxidopa were found to be efficient for neurogenic hypotension in double-blind, controlled studies, whereas other symptoms of autonomic failure may be managed with off-label treatments. To date, no curative treatment is available for MSA. Recent results of neuroprotective and -restorative trials have provided some hope for future advances. Considerations for future clinical trials are also discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.